Related content

慢性髓细胞白血病对伊马替尼产生耐药性的机制 Imatinib Resistance Mechanism on Chronic Myeloid Leukemia

By 夏君燕   朱平  

World Journal of Cancer Research, Vol. 02, Iss. 03, 2012-07 ,pp. : 15-19

汉斯出版社

Access to resources Recommend Favorite

Evaluation of Cytopenias Occurring in Imatinib Treated Chronic Myeloid Leukemia (CML) Patients

By Paul T.  

Indian Journal of Hematology and Blood Transfusion, Vol. 26, Iss. 2, 2010-06 ,pp. : 56-61

Springer Publishing Company

Access to resources Recommend Favorite

Imatinib Mesylate: A Review of Its Use in Chronic Myeloid Leukemia

By Curran M.P.   Croom K.F.   Goa K.L.  

American Journal of Cancer, Vol. 2, Iss. 6, 2003-01 ,pp. : 439-454

Adis International

Access to resources Recommend Favorite

MicroRNA181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib

By                                

Oncology Letters, Vol. 10, Iss. 5, 2015-01 ,pp. : 2835-2841

Spandidos Publications

Access to resources Recommend Favorite

Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application

By Ghatnekar Ola   Hjalte Frida   Taylor Matthew  

Acta Oncologica, Vol. 49, Iss. 6, 2010-08 ,pp. : 851-858

Informa Healthcare

Access to resources Recommend Favorite